Clinical Trials Directory

Trials / Completed

CompletedNCT02385604

The Predictive Value of CT-PET in Esophageal Cancer

CT-PET for Prediction of Histopathologic Response, Nodal Status and Oncologic Outcome Following Neoadjuvant Chemoradiation for Esophageal Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
250 (actual)
Sponsor
St. James's Hospital, Ireland · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A major focus of research in oncology is to identify patients who, following induction therapy, have a complete pathologic response, presenting opportunities for novel trials, including extended therapy or non-operative approaches, in addition to identifying cohorts who are resistant to the neoadjuvant therapy. The current gold standard for determining response to CRT is pathological evaluation following surgical resection, in particular the Mandard Tumour Regression Grade (TRG) or some modification thereof. At this time, however, there is no preclinical early response or post-treatment biomarker, nor endoscopic or radiologic assessment that predicts pathologic response prior to surgical resection.The aim of this study is to determine the accuracy of CT-PET for prediction of histopathologic response and/or oncologic outcome for patients with esophageal cancer.

Conditions

Timeline

Start date
2014-01-01
Primary completion
2016-01-01
Completion
2016-01-01
First posted
2015-03-11
Last updated
2016-03-10

Locations

1 site across 1 country: Ireland

Source: ClinicalTrials.gov record NCT02385604. Inclusion in this directory is not an endorsement.